98 related articles for article (PubMed ID: 16270153)
1. Construction of prophylactic human papillomavirus type 16 L1 capsid protein vaccine delivered by live attenuated Shigella flexneri strain sh42.
Yang XF; Qu XZ; Wang K; Zheng J; Si LS; Dong XP; Wang YL
Acta Biochim Biophys Sin (Shanghai); 2005 Nov; 37(11):743-50. PubMed ID: 16270153
[TBL] [Abstract][Full Text] [Related]
2. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
Yan X; Wang D; Liang F; Fu L; Guo C
Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
[TBL] [Abstract][Full Text] [Related]
3. [Construction of prophylactic recombinant HPV58-attenuated Shigella vector live vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model].
Li WS; Liu HL; Zhang YT; Yang XF; Wang YL; Si LS
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1163-6. PubMed ID: 18062891
[TBL] [Abstract][Full Text] [Related]
4. [Construction and characterization of a live attenuated Shigella flexneri 2a vaccine strain, sf301 Delta virG and dsbA33G].
Yang XF; Zhou L; Zheng J; Si LS; Wang YL
Wei Sheng Wu Xue Bao; 2005 Oct; 45(5):748-52. PubMed ID: 16342769
[TBL] [Abstract][Full Text] [Related]
5. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.
Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y
Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518
[TBL] [Abstract][Full Text] [Related]
6. Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
Li W; Liu H; Yang X; Zheng J; Wang Y; Si L
Acta Biochim Biophys Sin (Shanghai); 2009 Feb; 41(2):137-45. PubMed ID: 19204831
[TBL] [Abstract][Full Text] [Related]
7. [Humoral immune response and in vitro neutralizing antibody assay on co-delivery of protein HPV16L1 virus-like particle with HPV16L1 gene].
Song JM; Sun XL; Wang YL; Guo JF; Liu TJ; Si LS
Zhonghua Bing Li Xue Za Zhi; 2005 Jul; 34(7):421-4. PubMed ID: 16251048
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.
Noriega FR; Wang JY; Losonsky G; Maneval DR; Hone DM; Levine MM
Infect Immun; 1994 Nov; 62(11):5168-72. PubMed ID: 7927802
[TBL] [Abstract][Full Text] [Related]
10. [Prokaryotic expression of HPV 16L1 and optimization of expression conditions].
Peng FY; Jiang HR; Chen YX; Chen SZ; Lin ZH; Peng FL; Zhao WB; Chen BD
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):395-8. PubMed ID: 20731039
[TBL] [Abstract][Full Text] [Related]
11. Live Shigella flexneri 2a and Shigella sonnei I vaccine candidate strains with two attenuating markers. I. Construction of vaccine candidate strains with retained invasiveness but reduced intracellular multiplication.
Linde K; Dentchev V; Bondarenko V; Marinova S; Randhagen B; Bratoyeva M; Tsvetanov Y; Romanova Y
Vaccine; 1990 Feb; 8(1):25-9. PubMed ID: 2180230
[TBL] [Abstract][Full Text] [Related]
12. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.
Noriega FR; Losonsky G; Lauderbaugh C; Liao FM; Wang JY; Levine MM
Infect Immun; 1996 Aug; 64(8):3055-61. PubMed ID: 8757833
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.
Gupta G; Giannino V; Rishi N; Glueck R
Vaccine; 2016 Sep; 34(39):4724-4731. PubMed ID: 27523740
[TBL] [Abstract][Full Text] [Related]
14. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
15. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
[TBL] [Abstract][Full Text] [Related]
16. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
17. Nano-Sized Chimeric Human Papillomavirus-16 L1 Virus-like Particles Displaying
Zhou F; Zhang D
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896900
[TBL] [Abstract][Full Text] [Related]
18. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
19. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.
Ranallo RT; Fonseka S; Boren TL; Bedford LA; Kaminski RW; Thakkar S; Venkatesan MM
Vaccine; 2012 Jul; 30(34):5159-71. PubMed ID: 22658966
[TBL] [Abstract][Full Text] [Related]
20. [Construction and immunological evaluation of recombinant adenovirus containing codon-modified HPV 16 L1 gene].
Zhou YB; Zhou L; Li ZL; Sheng W; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Feb; 22(1):18-20. PubMed ID: 18414690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
